Skip to main content
Clinical Trials/NCT02063646
NCT02063646
Completed
Not Applicable

Effect of a Polyphenol-rich Food Supplement on Cognitive Function in Healthy Aging Adults: Randomized, Placebo-controlled, Double-blind Clinical Trial

Neurophenols Consortium2 sites in 2 countries204 target enrollmentFebruary 2014
ConditionsHealthy Elderly

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Healthy Elderly
Sponsor
Neurophenols Consortium
Enrollment
204
Locations
2
Primary Endpoint
CANTAB - Paired Associate Learning test (PAL)
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

Several preliminary studies have shown that diet can have beneficial effects on cognitive decline. Among food shown to have such effects are some polyphenols from selected botanicals.

Preclinical studies have concluded that polyphenols play a role in moderation of oxidative stress and inflammation, increased neuronal signaling, and improved metabolic function among other effects. Noteworthy, a positive and statistically significant association between the midlife level of polyphenol intake and cognitive function assessed 13 years later was found in a cohort of 2574 adults.

Several mechanisms may be involved in these positive effects of food polyphenols on cognitive function in older adults: experimental studies suggest that polyphenols display neuroprotective effects, enhancement of the neuronal function, stimulation of brain flow and inducing neurogenesis, and might prevent age-related damage to the central nervous system through their antioxidant and anti-inflammatory activities.

Based on these promising results, a food supplement from botanicals offering complementary polyphenol profile was developed. This food supplement is aimed to aid at maintenance of cognitive function in older adults.

Detailed Description

This project aims to investigate the effects of 6 months supplementation with a polyphenol-rich supplement vs. placebo to consume daily on human cognitive function. Polyphenol-rich supplement and placebo will be provided as capsules matched for appearance. The study will be conducted as a randomized, double-blind, parallel-groups (2 arms) placebo-controlled, multicentre interventional design. Two groups, each of 102 volunteers, are studied. One group of volunteers will consume the polyphenol-rich product while the other one will consume the placebo product. Each volunteer will be seen for 3 visits at the investigational site, will have 2 follow-up calls and mid-term dietary survey. Baseline and follow-up visit will include cognitive assessment with the CANTAB battery. CANTAB tests will cover several aspects of memory: visio-spatial learning and episodic memory, verbal recognition memory and visio-spatial working memory. Moreover, psychological and mood components will be evaluated (mnesic complaint, depression, fatigue). Physical activity and food habits will also be recorded. Finally, biological parameters will be assessed (lipid profile, glycemia, insulinemia, CRPus, thyroid stimulating hormone, transthyretin, plasma level of phenolic compounds).

Registry
clinicaltrials.gov
Start Date
February 2014
End Date
March 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Neurophenols Consortium
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Independent subjects, living at home;
  • Body Mass Index (BMI) 20-30 kg/m2 (limits included);
  • 26 \< MMSE score ≤ 29
  • Logical memory subtest of the Wechsler Memory Scale (16-69 years battery) sub-scores complying with the following:
  • Immediate recall score \< 29;
  • Delayed recall score \< 16;

Exclusion Criteria

  • Evidence of actual major depressive disorder according to the module A of the Mini International Neuropsychiatric Interview (MINI);
  • Subject consuming food supplements likely to have an effect on memory;
  • High physical activity practice;
  • Restrictive or unbalanced diet (hypocaloric, vegetarian, vegan, ...) self-declared at V0;
  • Diabetes;
  • Cardiovascular disease diagnosed within less than 2 years, with the following exceptions: subjects with controlled (medicated) high blood pressure and/ or controlled (medicated) can be included;
  • Personal history of Cerebrovascular Accident (CVA);
  • Unbalanced thyroid disease;
  • Anti-depressant treatment stopped since less than 3 months or still ongoing;
  • Personal history of schizophrenia or other psychiatric disorders;

Outcomes

Primary Outcomes

CANTAB - Paired Associate Learning test (PAL)

Time Frame: 24 weeks

Secondary Outcomes

  • Wechsler Memory Scale - Logical memory subtest(24 weeks)
  • McNair scale(24 weeks)
  • Mini-Mental State Examination(24 weeks)
  • CANTAB - Reverse Spatial Span test (Reverse SSP)(24 weeks)
  • Geriatric Depression Scale(24 weeks)
  • Multidimensional Fatigue Inventory (MFI-20)(24 weeks)
  • CANTAB - Verbal Recognition Memory (VRM)(24 weeks)
  • CANTAB - Spatial Span test (SSP)(24 weeks)

Study Sites (2)

Loading locations...

Similar Trials